FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884022211> ?p ?o ?g. }

• W2884022211 abstract "Background There has been considerable interest in providing antenatal dietary and lifestyle advice for women with obesity or who are overweight during pregnancy, as a strategy to limit gestational weight gain and improve maternal and infant health. However, such antenatal interventions appear to have a modest effect on gestational weight gain and other clinical pregnancy and birth outcomes and additional strategies are required. Metformin is an oral insulin‐sensitising medication that acts to decrease blood glucose concentrations. Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome, and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of caesarean birth and neonatal hypoglycaemia. Metformin may be an adjuvant therapy to current antenatal strategies in pregnant women with obesity or who are overweight, acting to reduce glucose production in the liver and improve glucose uptake in smooth muscle cells, and therefore improve the overall metabolic health of women in pregnancy and reduce the risk of known adverse pregnancy outcomes. Objectives To evaluate the role of metformin in pregnant women with obesity or who are overweight, on maternal and infant outcomes, including adverse effects of treatment and costs. Search methods We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (11 October 2017), and reference lists of retrieved studies. Selection criteria All published and unpublished randomised controlled trials evaluating metformin use (compared with placebo or no metformin) in women with obesity or who are overweight in pregnancy for improving outcomes, alone or in combination with other interventions were eligible for inclusion. Data collection and analysis Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. We used the GRADE approach to assess the quality of the evidence. Main results We included three studies which randomised women (1099) with a body mass index (BMI) of 30 kg/m2 (1 study) and 35 kg/m2 (2 studies), with outcomes available for 1034 participants. None of the studies assessed women with a BMI between 25 kg/m2and 29.9 kg/m2, therefore we could not assess the use of metformin in women considered overweight. We did not identify studies of metformin in combination with another treatment. Two other studies are ongoing. All three included studies were randomised controlled trials and compared metformin with placebo, commencing early in the second trimester. Doses ranged from 500 mg twice daily to 3.0 g per day. All three studies (two in the UK, one in Egypt) included women attending hospitals for antenatal care. Two studies were generally at a low risk of bias across the majority of domains. We assessed the third study as being at an unclear risk of selection bias, performance and detection bias due to insufficient information in the report. We assessed the trial as being at a low risk of attrition bias and other bias; we felt it was at a high risk of reporting bias. The primary outcome for this review was infant birthweight large‐for‐gestational‐age (> 90th centile for gestational age and infant sex). Women who received metformin or placebo had a similar risk of their baby being born large for his or her gestational age (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.70 to 1.30; 2 studies, 831 infants; high‐quality evidence). Women who received metformin may have a slightly lower gestational weight gain (mean difference (MD) ‐2.60 kg, 95% CI ‐5.29 to 0.10; 3 studies, 899 women; low‐quality evidence). Metformin may make little or no difference in the risk of women developing gestational hypertension (average RR 1.02, 95% CI 0.54 to 1.94; 3 studies, 1040 women; low‐quality evidence) or pre‐eclampsia (RR 0.74, 95% CI 0.09 to 6.28; 2 studies, 840 women; low‐quality evidence). Metformin probably makes little or no difference in the risk of women developing gestational diabetes (RR 0.85, 95% CI 0.61 to 1.19; 3 studies, 892 women; moderate‐quality evidence). One study of 400 women reported women receiving metformin were more likely to experience any adverse effect compared with women receiving placebo (RR 1.63, 95% CI 1.27 to 2.08; 1 study, 400 women). Adverse effects included abdominal pain, diarrhoea, or headache. When considering individual side effects, women receiving metformin were more likely to experience diarrhoea than women receiving placebo (RR 2.34, 95% CI 1.74 to 3.14; 797 women; 2 studies, 797 women; high‐quality evidence). No other important differences were identified between Metformin and placebo for other maternal secondary outcomes, including: caesarean birth, birth before 37 weeks of pregnancy, shoulder dystocia, perineal tear, or postpartum haemorrhage. In terms of other infant outcomes, there was little or no difference in the infant birthweight (MD 6.39 g, 95% CI ‐81.15 to 93.92; 2 studies, 834 infants; high‐quality evidence). There were no other important differences identified for other infant secondary outcomes in this review: hypoglycaemia (low blood sugar); hyperbilirubinaemia (jaundice); Apgar score less than 7 at five minutes; or stillbirth and neonatal death. Only one study reported admission to the neonatal intensive care unit (NICU), indicating similar rates of admission between women receiving metformin or placebo; no other admission data were reported to assess differences in costs. Authors' conclusions There is insufficient evidence to support the use of metformin for women with obesity in pregnancy for improving maternal and infant outcomes. Metformin was, however, associated with increased risk of adverse effects, particularly diarrhoea. The quality of the evidence in this review varied from high to low, with downgrading decisions based on study limitations and inconsistency. There were only a small number of studies included in this review. Furthermore, none of the included studies included women categorised as 'overweight' and no trials looked at metformin in combination with another treatment. Future research is required in order to further evaluate the role of metformin therapy in pregnant women with obesity or who are overweight, as a strategy to improve maternal and infant health, alone or as an adjuvant to dietary and lifestyle advice." @default.
• W2884022211 created "2018-08-03" @default.
• W2884022211 creator A5012654862 @default.
• W2884022211 creator A5020061384 @default.
• W2884022211 creator A5020994205 @default.
• W2884022211 creator A5063626527 @default.
• W2884022211 date "2018-07-24" @default.
• W2884022211 modified "2023-10-10" @default.
• W2884022211 title "Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes" @default.
• W2884022211 cites W1489622204 @default.
• W2884022211 cites W1784053566 @default.
• W2884022211 cites W1820234801 @default.
• W2884022211 cites W1964863515 @default.
• W2884022211 cites W1966224374 @default.
• W2884022211 cites W1977220675 @default.
• W2884022211 cites W1979782841 @default.
• W2884022211 cites W2020627940 @default.
• W2884022211 cites W2029110614 @default.
• W2884022211 cites W2030771432 @default.
• W2884022211 cites W2034674277 @default.
• W2884022211 cites W2040838640 @default.
• W2884022211 cites W2041830601 @default.
• W2884022211 cites W2046503553 @default.
• W2884022211 cites W205231004 @default.
• W2884022211 cites W2062486201 @default.
• W2884022211 cites W2085331654 @default.
• W2884022211 cites W2090024638 @default.
• W2884022211 cites W2099733101 @default.
• W2884022211 cites W2112259927 @default.
• W2884022211 cites W2125024886 @default.
• W2884022211 cites W2130500449 @default.
• W2884022211 cites W2141571811 @default.
• W2884022211 cites W2142504521 @default.
• W2884022211 cites W2144199745 @default.
• W2884022211 cites W2158353503 @default.
• W2884022211 cites W2160092493 @default.
• W2884022211 cites W2163710303 @default.
• W2884022211 cites W2169869070 @default.
• W2884022211 cites W2253351763 @default.
• W2884022211 cites W2320006945 @default.
• W2884022211 cites W2462575612 @default.
• W2884022211 cites W2515138962 @default.
• W2884022211 cites W2527888216 @default.
• W2884022211 cites W2552510437 @default.
• W2884022211 cites W2743636546 @default.
• W2884022211 cites W2808052171 @default.
• W2884022211 cites W2884022211 @default.
• W2884022211 cites W4241135750 @default.
• W2884022211 cites W4245367233 @default.
• W2884022211 cites W4302435679 @default.
• W2884022211 doi "https://doi.org/10.1002/14651858.cd010564.pub2" @default.
• W2884022211 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6513233" @default.
• W2884022211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30039871" @default.
• W2884022211 hasPublicationYear "2018" @default.
• W2884022211 type Work @default.
• W2884022211 sameAs 2884022211 @default.
• W2884022211 citedByCount "32" @default.
• W2884022211 countsByYear W28840222112017 @default.
• W2884022211 countsByYear W28840222112018 @default.
• W2884022211 countsByYear W28840222112019 @default.
• W2884022211 countsByYear W28840222112020 @default.
• W2884022211 countsByYear W28840222112021 @default.
• W2884022211 countsByYear W28840222112022 @default.
• W2884022211 countsByYear W28840222112023 @default.
• W2884022211 crossrefType "journal-article" @default.
• W2884022211 hasAuthorship W2884022211A5012654862 @default.
• W2884022211 hasAuthorship W2884022211A5020061384 @default.
• W2884022211 hasAuthorship W2884022211A5020994205 @default.
• W2884022211 hasAuthorship W2884022211A5063626527 @default.
• W2884022211 hasBestOaLocation W28840222112 @default.
• W2884022211 hasConcept C126322002 @default.
• W2884022211 hasConcept C131872663 @default.
• W2884022211 hasConcept C134018914 @default.
• W2884022211 hasConcept C147583825 @default.
• W2884022211 hasConcept C2777391703 @default.
• W2884022211 hasConcept C2779234561 @default.
• W2884022211 hasConcept C2779434492 @default.
• W2884022211 hasConcept C2779703513 @default.
• W2884022211 hasConcept C2780320433 @default.
• W2884022211 hasConcept C2780323712 @default.
• W2884022211 hasConcept C2780586474 @default.
• W2884022211 hasConcept C3018442814 @default.
• W2884022211 hasConcept C46973012 @default.
• W2884022211 hasConcept C511355011 @default.
• W2884022211 hasConcept C54355233 @default.
• W2884022211 hasConcept C555293320 @default.
• W2884022211 hasConcept C71924100 @default.
• W2884022211 hasConcept C86803240 @default.
• W2884022211 hasConceptScore W2884022211C126322002 @default.
• W2884022211 hasConceptScore W2884022211C131872663 @default.
• W2884022211 hasConceptScore W2884022211C134018914 @default.
• W2884022211 hasConceptScore W2884022211C147583825 @default.
• W2884022211 hasConceptScore W2884022211C2777391703 @default.
• W2884022211 hasConceptScore W2884022211C2779234561 @default.
• W2884022211 hasConceptScore W2884022211C2779434492 @default.
• W2884022211 hasConceptScore W2884022211C2779703513 @default.
• W2884022211 hasConceptScore W2884022211C2780320433 @default.
• W2884022211 hasConceptScore W2884022211C2780323712 @default.
• W2884022211 hasConceptScore W2884022211C2780586474 @default.
• W2884022211 hasConceptScore W2884022211C3018442814 @default.

• next